nice day, blue sky above.
The European Commission approves Gilead Sciences' (GILD +1.8%) Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of hepatitis C genotype 1 and 4 infection
certainly applies to me, I have had no position for the last couple of months ... just watching.
Patients treated with ferric citrate had a savings of $896 PPPY for infection-related adverse events, $1,021 PPPY for gastrointestinal-related adverse events, and $1,033 PPPY for cardiac-related adverse events, with lower overall rates of hospitalization in all 3 categories.
probably repetitive, but many thanks for this post. I do worry that GILD has been heavy handed with the large payors as you stated above, and hope it wont hurt them at the table.
Hey Bear, nice to hear from you. I also bought another big chunk about 15 minutes ago. my portfolio is slightly out of whack right now with the % of GILD in it.
lets look at NPSP after Adcom or SLXP last week ... you need to remove the emotion, know the real value of the asset you hold based on what is going on. Then act on that.
good question .. who should you trust. Well, it is your money so the only person you should truly trust is yourself. Because, at the end of the day, you will either win or lose and anyone you were following may not have any horses in the game and could be full of fluff - or could be working for a hedgie trying to scare you out of your shares.
In the end, know your price target and be disciplined to manage your risk. that is how you make money.